Advanced search
Publication Cover
Modern Rheumatology Case Reports Volume 4, 2020 - Issue 1
Journal homepage
121
Views
3
CrossRef citations to date
0
Altmetric
Case Reports

Atypical femoral fracture associated with delayed union for which the cessation of alendronate and daily administration of teriparatide contributed to fracture healing: histopathological evidence of the enhancement in bone formation parameters

Naoki KondoDivision of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan; Correspondence[email protected]
,
Dai MiyasakaDivision of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan;
,
Yo WatanabeDivision of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan;
,
Hiroe SatoHealth Administration Center, Niigata University, Niigata, Japan;
,
Toshihiro KandaDivision of Orthopedic Surgery, Seirei Hamamatsu Hospital, Hamamatsu, Japan
&
Naoto EndoDivision of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan;
Pages 141-146 | Received 24 Apr 2019, Accepted 11 Jul 2019, Published online: 16 Aug 2019

References

  • Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90:349–353.
  • Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25:2267–2294.
  • Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29:1–23.
  • Phillips HK, Harrison SJ, Akrawi H, et al. Retrospective review of patients with atypical bisphosphonate related proximal femoral fractures. Injury. 2017;48:1159–1164.
  • Egol KA, Park JH, Rosenberg ZS, et al. Healing delayed but generally reliable after bisphosphonate-associated complete femur fractures treated with IM nails. Clin Orthop Relat Res. 2014;472:2728–2734.
  • Bogdan Y, Tornetta P, 3rd, Einhorn TA, et al. Healing time and complications in operatively treated atypical femur fractures associated with bisphosphonate use: a multicenter retrospective cohort. J Orthop Trauma. 2016;30:177–181.
  • Miyakoshi N, Aizawa T, Sasaki S, et al. Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: a comparison between treatment with and without teriparatide. J Bone Miner Metab. 2015;33:553–559.
  • Greenspan SL, Vujevich K, Britton C, et al. Teriparatide for treatment of patients with bisphosphonate-associate atypical fracture of the femur. Osteoporos Int. 2018;29:501–506.
  • Starr J, Tay YKD, Shane E. Current understanding of epidemiology, pathophysiology, and management of atypical femoral fractures. Curr Osteoporos Rep. 2018;16:519–529.
  • Recker RR, Kimmel DB, Parfitt AM, et al. Static and tetracycline-based bone histomorphometric data from 34 normal postmenopausal females. J Bone Miner Res. 2009;3:133–144.
  • Im GI, Lee SH. Effect of teriparatide on healing of atypical femoral fractures: a systemic review. J Bone Metab. 2015;22:183–189.
  • Yeh WL, Su CY, Chang CW, et al. Surgical outcome of atypical subtrochanteric and femoral fracture related to bisphosphonates use in osteoporotic patients with or without teriparatide treatment. BMC Musculoskelet Disord. 2017;18:527.
  • Tsuchie H, Miyakoshi N, Iba K, et al. The effects of teriparatide on acceleration of bone healing following atypical femoral fracture: comparison between daily and weekly administration. Osteoporos Int. 2018;29:2659–2665.
  • Watts NB, Aggers D, McCarthy EF, et al. Response to treatment with teriparatide in patients with atypical femur fractures previously treated with bisphosphonates. J Bone Miner Res. 2017;32:1027–1033.
  • Miller PD, McCarthy EF. Bisphosphonate-associated atypical sub-trochanteric femur fractures: paired bone biopsy quantitative histomorphometry before and after teriparatide administration. Semin Arthritis Rheum. 2015;44:477–482.
  • Yamamoto T, Taketsuna M, Guo X, et al. The safety and effectiveness profile of daily teriparatide in a prospective observational study in Japanese patients with osteoporosis at high risk for fracture: interim report. J Bone Miner Metab. 2014;32:699–708.
  • Kondo N, Fukuhara T, Watanabe Y, et al. Bone formation parameter of the biopsied ilium differ between subtrochanteric and diaphyseal femoral fractures in bisphosphonate-treated patients. Tohoku J Exp Med. 2017;243:247–254.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.